|
|
12255 El Camino Real, Suite 250
San Diego, CA 92130 USA
phone:858.436.1000
fax:858.436.1001
|
|
| Symbol |
CXM |
| Exchange |
AMEX |
| Founded |
2003 |
| Employees |
15 |
|
|
| www.cardiumthx.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutic products and technologies for wound healing and cardiovascular indications |
|
| Management |
| Christopher J. Reinhard, Chairman of the Board, CEO, President and Treasurer; Tyler M. Dylan, Ph.D., J.D., Director, Chief Business Officer, General Counsel, Executive Vice President and Secretary; Dennis M. Mulroy, CPA - CFO; Gabor M. Rubanyi, M.D., Ph.D., Chief Scientific Officer; Robert L. Engler, M.D.,
Chief Medical Advisor; Mark McCutchen, Vice President, Business Development;
Ted Williams, Vice President, Manufacturing and Technical Operations;
Lois A. Chandler, Vice President, Biologics Development |
| |
|
|
|
|
|
|
|
| Keywords |
| tissue repair, coronary artery disease, angioplasty, cardiovascular, nutraceuticals, metabolics, fitness, aesthetics |
|
|
|
|
|
|
| Description |
|
Cardium Therapeutics acquires and strategically develops innovative commercial endeavors within the world of biomedicine; specifically, the Company focuses on such endeavors that have the potential to address significant unmet medical needs and forge definable pathways toward economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, both of which develop therapeutic products for wound healing, bone repair, and cardiovascular indications. The Company's portfolio also includes its in-house MedPodium lifestyle product platform. Lead product candidates include Excellagen topical gel for wound care management, which achieved FDA 510K clearance in October 2011, and Generx DNA-based angiogenic biologic for patients with coronary artery disease. In August 2011, this later-stage medtech and investment company received the last payment of its $11.25M sale of InnerCool Therapies to Royal Phillips Electronics, marking the finalization of the Company's first asset monetization from its biomedical investment portfolio. |
|
| Products / Services |
|
Lead commercial product Excellagen topical gel for advanced wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development ...
view more
|
|
| Technology / Differentiation |
| Cardium's current medical opportunities portfolio, focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. |
|
|
| Status |
| Cardium's current investment portfolio includes the Tissue Repair Company, Cardium Biologics, and its in-house MedPodium healthy lifestyle brand platform. The Company's lead product candidates include: (1) Excellagen topical gel, for wound care management, which recently received FDA 510(k) clearance; and (2) Generx, a DNA-based angiogenic cardiovascular biologic for patients in international markets with coronary artery disease. The Company recently received clearance from the Russian Ministry of Health to initiate the Phase 3/registration ASPIRE study for patients with myocardial ischemia due to advanced coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Companys biomedical investment portfolio. |
|
|
|
|
|
|
Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home/onemedpl/public_html/database/comp_profile_include.php on line 1083
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
